Effect of infliximab treatment on titres of IgM RF and anti-CCP antibodies in RA
| Cut off point | Patients (n) | Baseline | Week 30 | p Value |
|---|---|---|---|---|
| *Manufacturer’s cut off point. Median values (range) are given. Wilcoxon signed rank test. | ||||
| IgM RF (assay using particles sensitised with rabbit IgG) | ||||
| ⩾40 | 54 | 320 (40–5120) | 160 (0–5120) | <0.001 |
| ⩾80 | 48 | 320 (80–5120) | 160 (0–5120) | <0.001 |
| ⩾160 | 41 | 320 (160–5120) | 160 (0–5120) | <0.001 |
| Total cohort | 62 | 160 (0–5120) | 160 (0–5120) | <0.001 |
| IgM RF (assay using particles sensitised with human IgG) | ||||
| ⩾40 | 55 | 160 (40–5120) | 160 (0–5120) | 0.038 |
| ⩾80 | 46 | 320 (80–5120) | 160 (0–5120) | 0.017 |
| ⩾160 | 39 | 320 (160–5120) | 160 (0–5120) | 0.023 |
| Total cohort | 62 | 160 (0–5120) | 160 (0–5120) | 0.038 |
| Anti-CCP antibodies | ||||
| >50 U* | 41 | 880 (65–5236) | 719 (54–8802) | 0.530 |
| Total cohort | 62 | 535 (5–5236) | 447 (7–8802) | 0.240 |